Supplementary Figure S2 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

Covariate Effects on Full Nivolumab Pharmacokinetic Model Parameters. Reference patient is a 60-year-old male, white/other race, baseline body weight = 75 kg, PS = 0, baseline ALB = 4 g/dL, baseline eGFR = 90 mL/min/1.73 m2, received nivolumab monotherapy, and with 1L MEL. Parameter estimate in a reference patient is considered as 100% (vertical solid line), and dashed vertical lines are at 80% and 125% of this value.